Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Reata Pharmaceuticals stock
Learn how to easily invest in Reata Pharmaceuticals stock.
Reata Pharmaceuticals Inc is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 346 staff and has a trailing 12-month revenue of around $10 million.
How to buy shares in Reata Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RETA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Reata Pharmaceuticals stock price (NASDAQ: RETA)Use our graph to track the performance of RETA stocks over time.
Reata Pharmaceuticals shares at a glance
|Latest market close||$25.52|
|52-week range||$18.47 - $114.80|
|50-day moving average||$25.76|
|200-day moving average||$28.98|
|Wall St. target price||$50.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-8.35|
Buy Reata Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Reata Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Reata Pharmaceuticals price performance over time
|1 week (2022-09-29)||1.96%|
|1 month (2022-09-06)||14.13%|
|3 months (2022-07-05)||-30.06%|
|6 months (2022-04-06)||-28.42%|
|1 year (2021-10-06)||-73.56%|
|2 years (2020-10-06)||-77.02%|
|3 years (2019-10-04)||80.24|
|5 years (2017-10-06)||31.9|
Reata Pharmaceuticals financials
|Revenue TTM||$10 million|
|Gross profit TTM||$-144,503,000|
|Return on assets TTM||-22.86%|
|Return on equity TTM||-159.3%|
|Market capitalisation||$936.1 million|
TTM: trailing 12 months
Reata Pharmaceuticals share dividends
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Reata Pharmaceuticals share price volatility
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $18.47 up to $114.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.155. This would suggest that Reata Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals overview
Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd.
Reata Pharmaceuticals in the news
Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks
Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm
Positive week for Reata Pharmaceuticals, Inc. (NASDAQ:RETA) institutional investors who lost 76% over the past year
Frequently asked questionsWhat percentage of Reata Pharmaceuticals is owned by insiders or institutions?
Currently 3.372% of Reata Pharmaceuticals shares are held by insiders and 87.065% by institutions. How many people work for Reata Pharmaceuticals?
Latest data suggests 346 work at Reata Pharmaceuticals. When does the fiscal year end for Reata Pharmaceuticals?
Reata Pharmaceuticals's fiscal year ends in December. Where is Reata Pharmaceuticals based?
Reata Pharmaceuticals's address is: 5320 Legacy Drive, Plano, TX, United States, 75024 What is Reata Pharmaceuticals's ISIN number?
Reata Pharmaceuticals's international securities identification number is: US75615P1030 What is Reata Pharmaceuticals's CUSIP number?
Reata Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75615P103
More guides on Finder
Alternatives to Webull
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Best renewable energy stocks for 2022
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
The best dividend stocks for 2022
Our list of 10 dividend stocks to watch in 2022.
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Ask an Expert